Correcting for heterogeneity and non‐comparability bias in multicenter clinical trials with a rescaled random‐effect excess hazard model
Juste Goungounga(Centre National de la Recherche Scientifique), Roch Giorgi(Inserm), Nathalie Grafféo(Inserm), Hadrien Charvat(Juntendo University)
Cited by 15
Related Papers
Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study
|The Lancet Oncology|2021|684
Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality in a Japanese Cohort
|JAMA Internal Medicine|2019|204
Socioeconomic inequalities in cancer mortality between and within countries in Europe: a population-based study
|The Lancet Regional Health - Europe|2022|155
Impact of population aging on trends in diabetes prevalence: A meta‐regression analysis of 160,000 Japanese adults
|Journal of Diabetes Investigation|2015|138
Diabetes mellitus and cancer risk: Pooled analysis of eight cohort studies in Japan
|Cancer Science|2013|108